A Phase 2 interventional study of niacin (+) laropiprant and Comparator: placebo (unspecified) in Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 25 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-17.
Sponsored by Merck Sharp & Dohme LLC · Phase 2, Interventional, and Treatment
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
The duration of treatment is 7 days.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 575 is above the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Also known as: MK0524A
Acute cutaneous symptoms induced by niacin for 7 days.
Time frame: 7 days
Tolerability
Time frame: 7 days
No study locations are listed for this record.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC